The following summarizes the report contents by section:
SECTION I: Market Status, Trends and Forecasts
Analysis of sales trends and opportunities in SPECT and PET markets, competitive challenges, new products in the pipeline and prospects for future growth. Also provides sales forecasts in all product categories to 2018. Products include:
- Nuclear cardiology agents for SPECT and PET. (myocardial perfusion, myocardial viability, neuronal imaging and metabolic imaging). New products include Zemeva for myocardial infarction, AdreView for neuronal instability and congestive heart failure, new PET myocardial perfusion and neuronal imaging agents.
- Products for functional SPECT imaging. SPECT and PET neurology imaging including new products for Alzheimer's and Parkinson’s imaging from Avid, G.E. Bayer and Alseres.
- Oncology products including ProstaScint, Octreoscan and new products for imaging prostate cancer including Trofex from Molecular Insight. Also, PET apoptosis imaging with Aposense, Cellectar PLE products and Cell>Point new molecular imaging platforms.
SECTION II: Radiopharmaceutical Products and Technology
- Technical principles and functional characteristics of radiopharmaceutical agents.
- Radioisotope selection and optimization; production methods and trade-offs.
- Challenges in recent technetium shortage and options for new sources of molybdenum-99
SECTION III: Clinical Applications
- Discussion of clinical applications for radiopharmaceutical products and technologies.
- Options in radiopharmaceutical selection for both SPECT and PET imaging.
- Analysis of product characteristics, performance benefits and trade-offs.
SECTION IV: Current Developments and Emerging Technologies
- Description of products in development within each major SPECT and PET market segment including cardiology, neurology and oncology.
- Description of new SPECT and PET agents, such as new myocardial imaging agents, angiogenesis imaging for cellular response to therapy, apoptosis imaging and therapy, PLE (phospho-lipid ether) targeting and therapy, new SPECT glucose-based imaging.
SECTION V: Industry Analysis
- Analysis of current suppliers with individual product sales and market shares in 2009
- Market distribution, pricing strategies and new products in the pipeline.
SECTION VI: End-User Analysis
- Analysis of end-user groups and comparative requirements for medical imaging.
- Procedure mix and product utilization in hospitals and clinics.
SECTION VII: Company Profiles
- Background information on companies in the field and review of recent performance.
- Discussion of each company's market activities and management strategies.
|
Back to Top
BTSI330.doc
-OR-
BTSI330.pdf
Send
this page to a friend